Abstract 1103P
Background
In RELATIVITY-047 (NCT03470922), NIVO + RELA previously demonstrated a statistically significant improvement in the primary endpoint of PFS per BICR vs NIVO, with a clinically meaningful (non-significant) statistical improvement in OS and a numerically higher ORR (secondary endpoints) in pts with previously untreated metastatic or unresectable melanoma. Post hoc analyses exploring the efficacy of NIVO + RELA vs NIVO according to baseline (BL) sites of metastasis (mets) and the time to development of CNS mets are reported herein.
Methods
Pts were randomized 1:1 to receive NIVO 480 mg + RELA 160 mg fixed-dose combination (FDC) or NIVO 480 mg intravenously Q4W. Exploratory post hoc analyses were performed for PFS, OS, ORR, and melanoma-specific survival (MSS) by the no. of mets sites and the presence or absence of liver and lung mets. Time to development of new CNS mets per BICR was also assessed in both arms. Follow-up (f/u) brain imaging was not mandated per protocol.
Results
Median f/u was 25.3 mo; 581/714 pts were included in the BL mets analysis (mucosal and acral pts were excluded). Efficacy favored NIVO + RELA over NIVO in the majority of subgroups analyzed (Table). In pts without CNS mets at BL (348 in each arm), 17 pts (5%) in the NIVO + RELA arm and 31 pts (9%) in the NIVO arm developed new CNS mets per BICR over the course of tumor assessment f/u. Median time to the development of new CNS mets per BICR was 11.1 mo (range, 2.0–31.5) with NIVO + RELA and 6.6 mo (range, 0.6–32.7) with NIVO.
Conclusions
Efficacy outcomes generally favored NIVO + RELA over NIVO in pts with BL liver or lung mets and regardless of no. of BL sites of disease. Fewer pts on NIVO + RELA vs NIVO developed new CNS mets (and took a longer time to develop them), suggesting CNS activity with the FDC; however, incidence was low. Activity of NIVO + RELA in pts with CNS mets needs to be confirmed in a dedicated CNS study. Additional analyses will be presented. Table: 1103P
PFS | OS | MSS | ORR | ||
n | HR (95% CI) | HR (95% CI) | HR (95% CI) | ORR difference, % (95% CI) | |
No. of mets sites | |||||
1 | 184 | 0.85 (0.57–1.27) | 0.92 (0.56–1.52) | 0.85 (0.48–1.51) | 14.1 (-0.3 to 27.8) |
2–3 | 286 | 0.71 (0.53–0.95) | 0.69 (0.49–0.98) | 0.59 (0.40–0.88) | 11.5 (0.1 to 22.4) |
≥ 4 | 109 | 0.91 (0.59–1.42) | 0.74 (0.46–1.21) | 0.77 (0.46–1.28) | -0.1 (-17.6 to 17.1) |
Liver mets | |||||
Present | 122 | 0.81 (0.53–1.23) | 0.62 (0.37–1.03) | 0.72 (0.41–1.27) | 9.4 (-7.7 to 25.6) |
Absent | 459 | 0.81 (0.64–1.02) | 0.84 (0.64–1.11) | 0.72 (0.53–0.99) | 9.3 (0.2 to 18.1) |
Lung mets | |||||
Present | 254 | 0.77 (0.57–1.05) | 0.72 (0.50–1.04) | 0.71 (0.47–1.05) | 12.8 (0.7 to 24.4) |
Absent | 327 | 0.85 (0.64–1.12) | 0.84 (0.61–1.17) | 0.73 (0.5–1.07) | 6.8 (-4.0 to 17.3) |
Unstratified HR; NIVO + RELA vs NIVO.
Clinical trial identification
NCT03470922.
Editorial acknowledgement
Jessica R. Augello, PhD, Ashfield MedComms.
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
G.V. Long: Financial Interests, Personal, Speaker, Consultant, Advisor: Agenus Inc., Amgen Inc., Array Biopharma, Boehringer Ingelheim International GmbH, BMS, Evaxion Biotech A/S, Hexal AG (Sandoz Company), Highlight Therapeutics S.L, Innovent Biologics USA Inc., Merck Sharp & Dohme (Australia) Pty Limited, Novartis Pharma AG; Financial Interests, Personal, Invited Speaker: BMS, Pierre Fabre; Financial Interests, Personal, Advisory Board: Agenus Inc., Amgen Inc., Array Biopharma, Boehringer Ingelheim International GmbH, BMS, Evaxion Biotech A/S, Hexal AG (Sandoz Company), Highlight Therapeutics S.L, Innovent Biologics USA Inc., Merck Sharp & Dohme (Australia) Pty Limited, Novartis Pharma AG. F.S. Hodi: Financial Interests, Institutional, Research Grant: BMS, Novartis; Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, Merck, Novartis, Genentech/Roche, CatalYm, Immunocore, Kairos, Zumutor, Corner Therapeutics, Curis, AstraZeneca; Financial Interests, Personal, Advisory Board: BioEntre, Iovance, Gossamer, Rheos, Surface, Compass Therapeutics, Apricity, Bicara, Checkpoint Therapeutics. E.J. Lipson: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck, Sanofi, Regeneron, Genentech, Eisai, Instil Bio, Natera, Nektar Therapeutics, Pfizer, Rain Therapeutics, CareDx, Immunocore, Novartis, Replimune, HUYA Bioscience International; Financial Interests, Personal, Other, Consultant: OncoSec; Financial Interests, Institutional, Coordinating PI: Bristol Myers Squibb; Financial Interests, Institutional, Local PI: Regeneron, Merck, Sanofi. D. Schadendorf: Financial Interests, Personal, Invited Speaker: BMS, Novartis, MSD, Roche, Merck Serono, Sanofi; Financial Interests, Personal, Advisory Board: BMS, Novartis, MSD, Immunocore, Pierre Fabre, Sanofi/Regeneron, Pfizer, Philogen, Neracare; Financial Interests, Personal, Steering Committee Member: Novartis, BMS, MSD; Financial Interests, Institutional, Coordinating PI: Novartis, BMS, MSD, Pierre Fabre; Financial Interests, Institutional, Research Grant: BMS, MSD; Financial Interests, Institutional, Local PI: Sanofi, Philogen; Non-Financial Interests, Member of Board of Directors: EORTC-MG. P.A. Ascierto: Financial Interests, Personal, Other, Consultant and Advisory Role: BMS, Roche Genentech, MSD, Novartis, Merck Serono, Pierre Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Nektar, Boehringer Ingelheim, Regeneron; Financial Interests, Personal, Other, Consultant and Advisory Role. Travel support: Pfizer/Array; Financial Interests, Personal, Other, Consultant Role: Italfarmaco; Financial Interests, Personal, Other, Advisory Role: Eisai, Seagen; Financial Interests, Personal, Other, Consultant Role: Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore; Financial Interests, Personal, Other, Consultant role: Medicenna; Financial Interests, Personal, Other, Consultant role and travel support: Bio-AI Health; Financial Interests, Personal, Advisory Board, Consultant and Advisory Role: iTeos; Financial Interests, Personal, Advisory Board, Consultant and Advisory role: ValoTx; Financial Interests, Personal, Advisory Board, Consultant and Advisor role. Travel support: Replimune; Financial Interests, Personal, Advisory Board, Advisor role: Bayer; Financial Interests, Personal, Advisory Board: Erasca; Financial Interests, Institutional, Funding, Clinical trial and translational research: BMS; Financial Interests, Institutional, Funding, Clinical Trial: Roche Genentech, Pfizer/Array, Sanofi; Non-Financial Interests, Leadership Role, President since 2010: Fondazione Melanoma Onlus Italy; Non-Financial Interests, Leadership Role, President since 2014: Campania Society of ImmunoTherapy of Cancer (SCITO) Italy; Non-Financial Interests, Other, Member of Steering Committee since 2016: Society for Melanoma Research (SMR); Non-Financial Interests, Member of Board of Directors, November 2017 - December 2021: Society for Immunotherapy of Cancer (SITC); Non-Financial Interests, Member: ASCO, SITC, EORTC Melanoma Cooperative Group, AIOM, SMR. M. Maio: Financial Interests, Personal, Advisory Board: BMS, Roche, GSK, Sanofi, Alfasigma, Amgen, SciClone, Eli Lilly, MSD, Incyte, Pierre Fabre, AstraZeneca; Financial Interests, Personal, Stocks/Shares: EpiGen, Theravance. M. Hernberg: Financial Interests, Personal, Advisory Board: BMS, Pierre Fabre, MSD, Novartis, Med Engine; Financial Interests, Personal, Invited Speaker: Novartis, MSD, BMS. S. Prey: Financial Interests, Institutional, Advisory Board: BMS, MSD, Novartis. V.G. Atkinson: Financial Interests, Personal, Advisory Board: BMS, MSD, Nektar, Novartis, Pierre Fabre, QBiotics; Financial Interests, Personal, Invited Speaker: BMS, MSD, Novartis, Pierre Fabre, Limbic; Financial Interests, Personal, Other, Travel Support: BMS. J.C. Hassel: Financial Interests, Personal, Invited Speaker: BMS, Novartis, Sanofi, MSD, Sun Pharma, Amgen, GSK, Pierre Fabre, Immunocore; Financial Interests, Personal, Advisory Board: MSD, Pierre Fabre, Sun Pharma, GSK, Onkowissen; Financial Interests, Institutional, Advisory Board: Novartis, BMS, Immunocore, Philogen, Sanofi; Financial Interests, Institutional, Research Grant: BMS, Sun Pharma; Financial Interests, Institutional, Local PI: Philogen, Genentech, 4SC, BioNTech, Idera, Iovance, Nektar, Pierre Fabre, Regeneron, Sanofi, Replimune; Financial Interests, Institutional, Coordinating PI: BMS, Immunocore, Novartis, Genmab; Financial Interests, Personal, Steering Committee Member: Immunocore, IO Biotech; Non-Financial Interests, Leadership Role: DeCOG; Non-Financial Interests, Member: ASCO. G. Cinat: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Novartis, Merck Sharp & Dohme (MSD); Financial Interests, Personal, Expert Testimony: Bristol Myers Squibb, Novartis, Merck Sharp & Dohme (MSD); Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Novartis, Merck Sharp & Dohme (MSD), Roche; Financial Interests, Personal, Other, Concensus Conference: Americas Health Foundation; Financial Interests, Personal, Full or part-time Employment: Angel H. Roffo Oncology Institute, University of Buenos Aires; Financial Interests, Personal, Local PI: Bristol Myers Squibb (BMS), Novartis, Merck Sharp & Dohme (MSD), Pfizer; Non-Financial Interests, Personal, Member: ASCO, Argentina Association of Clinical Oncology (Asociación Argentina de Oncología Clínica - AAOC). B. Ratto, S. Rodriguez, S. Dolfi: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. P.T. Wang: Financial Interests, Personal, Full or part-time Employment, Biostatistician employed full-time: BMS (Bristol Myers Squibb); Financial Interests, Personal, Stocks/Shares: BMS (Bristol Myers Squibb). H.A. Tawbi: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck, Novartis, Genentech, Eisai, Karyopharm, Iovance, Pfizer, Jazz Pharmaceuticals; Financial Interests, Institutional, Trial Chair: Bristol Myers Squibb; Financial Interests, Institutional, Local PI: Merck, RAPT Pharmaceuticals; Financial Interests, Institutional, Steering Committee Member: Novartis, Genentech; Financial Interests, Institutional, Funding: GSK, Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13